Post

PepGen earns FDA fast track designation for myotonic dystrophy type 1 candidate

The US Food and Drug Administration (FDA) has granted fast track designation to PepGen’s candidate for the treatment of myotonic …

MHRA bans OTC sale of codeine after recreational abuse reports

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has announced that codeine linctus is to be reclassified as a …

Bavarian Nordic’s revenue soars post-mpox outbreaks

Bavarian Nordic reported record financial results in 2023, earning a preliminary revenue of DKr7.06bn ($1bn) compared to DKr3.15bn ($456m) in …

Will smart tech revolutionise drug delivery for ulcerative colitis patients?

Therapies within the ulcerative colitis (UC) space are ever-evolving for the improvement of local, targeted therapy. UC is a chronic …

Polpharma looks to challenge Takeda’s Entyvio in IBD

Netherland-based Polpharma Biologics has released topline results from the Phase III trial of its biosimilar candidate PB016, showing that the …